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ABSTRACT
Introduction: Topical anesthesia is widely used in dentistry to reduce pain caused by needle insertion
and injection of the anesthetic. However, successful anesthesia is not always achieved using the
formulations that are currently commercially available. As a result, local anesthesia is still one of the
procedures that is most feared by dental patients. Drug delivery systems (DDSs) provide ways of
improving the efficacy of topical agents.
Areas covered: An overview of the structure and permeability of oral mucosa is given, followed by a
review of DDSs designed for dental topical anesthesia and their related clinical trials. Chemical
approaches to enhance permeation and anesthesia efficacy, or to promote superficial anesthesia,
include nanostructured carriers (liposomes, cyclodextrins, polymeric nanoparticle systems, solid lipid
nanoparticles, and nanostructured lipid carriers) and different pharmaceutical dosage forms (patches,
bio- and mucoadhesive systems, and hydrogels). Physical methods include pre-cooling, vibration,
iontophoresis, and microneedle arrays.
Expert opinion: The combination of different chemical and physical methods is an attractive option for
effective topical anesthesia in oral mucosa. This comprehensive review should provide the readers with
the most relevant options currently available to assist pain-free dental anesthesia. The findings should
be considered for future clinical trials.
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1. Introduction
The isolation of cocaine and recognition of its local anesthetic
(LA) properties in the second half of nineteenth century revo-
lutionized dentistry, because patients could be treated pain-
lessly while awake [1]. Since then, better anesthetic agents
and armamentaria have been developed in order to achieve
the best quality of local anesthesia.
However, painless treatment does not necessarily mean
painless anesthesia. LA solutions must be injected through a
needle, causing pain due to needle penetration/placement
and solution deposition. Figure 1(b) and (d) illustrate LA injec-
tions in the maxillary buccal fold and palate, respectively. The
aim of dental topical anesthesia (Figure 1(a) and (c)) is to
eliminate the pain associated with dental anesthesia proce-
dures [2].
Dental topical anesthesia formulations are commercially
available for oral use as gels, ointments, solutions, and adhe-
sive patches [1]. The most common anesthetic agents used in
topical formulations are benzocaine, lidocaine, tetracaine
hydrochloride, and the combination of benzocaine, butamben,
and tetracaine. The eutectic mixture of lidocaine and prilo-
caine (EMLA® cream, AstraZeneca), which is designed for skin
anesthesia, is also used on oral mucosa [3].
The efficacy of these formulations has been evaluated in
many studies, with conflicting results. Most studies are difficult
to compare, mainly due to the absence of a placebo or rando-
mization, insufficient application time, and single-blind design
[4]. However, double-blind randomized placebo-controlled stu-
dies have demonstrated that topical anesthetics reduce the
pain induced by needle insertion but are unable to control
the pain from anesthetic injection in the palate [5–8]. Even
EMLA, which has been used as a positive control in many
studies of topical anesthetic efficacy, is not effective in reducing
pain during LA injection in the palate [8].
However, recent studies showed improvements in in vitro
permeation and in vivo palatal efficacy of liposomal lidocaine
formulations, offering new possibilities for effective oral topi-
cal anesthesia [9,10]. In addition, complexation of LAs with
cyclodextrins (CDs) has also shown potential for improvement
of topical anesthesia, by either providing rapid onset of
anesthesia or prolonging its effect [11].
The present comprehensive review describes the state of
art of a variety of drug delivery systems (DDSs) designed to
enhance permeation and improve dental topical anesthetic
efficacy or promote superficial anesthesia. Chemical methods
include nanostructured carriers (liposomes, CDs, polymeric
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nanoparticle (PN) systems, solid lipid nanoparticles [SLNs], and
nanostructured lipid carriers [NLCs]), as well as different phar-
maceutical dosage forms (patches, bio- and mucoadhesive
systems, and hydrogels). Physical methods include the use of
precooling, vibration, iontophoresis, and microneedle arrays.
Emphasis is given to the clinical trials that have evaluated
these methods in different sites of the oral mucosa. Chemical
permeation enhancers will not be discussed, since this topic
was previously reviewed by Hassan and colleagues [12].
2. Oral mucosa: structure, barrier properties,
permeability, and permeation pathways
Knowledge of the structure, permeability, permeation path-
ways, and barrier properties of the oral mucosa is essential in
the development of a successful oral topical anesthetic for-
mulation. Permeability refers to the ability of the oral mucosa
to be penetrated by drugs such as LA, while permeation path-
ways (or penetration routes) refer to the routes taken by the
drugs to permeate the tissue. For detailed information on
these topics, the reader is referred to the literature published
by Squier and colleagues [13–15].
The oral cavity is covered by a protective lining tissue called
the oral mucosa. This is composed of a stratified squamous
epithelium and connective tissue (lamina propria) consisting of
cells, blood vessels, fibers, and nerves (the site of action of
LAs) dispersed in an amorphous tissue [15]. There are three
different types of oral mucosa, classified according to anato-
mical position and epithelium structure. The masticatory
mucosa has a keratinized epithelium and lamina propria
attached to the periosteum of the underlying bone (maxillae
or alveolar bone) and is found in the hard palate and gingiva
(~25% of the oral cavity), where it is constantly subjected to
mechanical forces. This tissue, called the mucoperiosteum,
provides a firm and inelastic attachment (Figure 2(a)). To
ensure resistance to shear forces and abrasion, its lamina
propria is dense and filled with a compact complex of collagen
fibers in the form of large, closely packed bundles. Due to
these characteristics, LA injections in this tissue are more likely
to be painful [14,15].
Approximately, 60% of the oral mucosa area is composed
of the lining mucosa, which covers the soft palate, ventral side
of the tongue, buccal region, inner side of the lips, and floor of
the mouth. This tissue is composed of nonkeratinized epithe-
lium and lamina propria, with the ability to deform during
normal movements. Its softness is related to a submucosa
region under the lamina propria, composed of loose fat cells,
glandular tissue, blood vessels, and nerves (Figure 2(b)). This
layer is absent in both masticatory and specialized mucosa,
which are firmly connected to the periosteum and tongue
muscle, respectively [14,15].
The dorsal side of the tongue is covered by a specialized
mucosa. This has unique properties due to the presence of
Article highlights
● Topical anesthesia offers the possibility of pain-free dental
anesthesia.
● The greatest challenge in formulation development is to overcome
the oral mucosa epithelium barrier, wrongly considered a highly
permeable tissue.
● Although there are several studies reporting formulation develop-
ment and promising in vitro performance, only a few formulations
have been evaluated in clinical trials.
● All the clinical trials involving chemical methods (DDSs and pharma-
ceutical dosage forms) described throughout the review are summar-
ized in Table 1. Nine studies are highlighted because they evaluated
formulations still under development (not yet commercially avail-
able), in Phase I clinical trials. Seven of these tested liposomal
formulations and two used polymeric films.
● Clinical trials indicate that liposomal encapsulation and the pre-cool-
ing technique promote improved topical anesthetic efficacy in differ-
ent oral mucosa sites, including the palatal mucosa, and seem to be
auspicious strategies in dental topical anesthesia.
● Further studies are needed to evaluate the effectiveness of combina-
tions of different chemical and physical methods, since this repre-
sents the most promising option for overcoming topical anesthesia
challenges.
This box summarizes key points contained in the article.
Figure 1. Topical and local anesthesia procedures commonly performed for dental treatment. Maxillary buccal fold topical anesthesia (1a) and injection (1b). Palate
fold topical anesthesia (1c) and injection (1d).
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both keratinized and nonkeratinized epithelia, papillae, and
taste buds responsible for the taste sensations of sweetness,
saltiness, sourness, bitterness, and umami [14,15].
The barrier function of the oral mucosa is due to the upper
region of the epithelium, comprising an intercellular lipid mate-
rial released by the membrane-coating granules [16]. An addi-
tional barrier is provided by the strong adhesion among the
keratinocytes, the main epithelium cell type, provided by des-
mosomes [15]. Permeation across the oral mucosa can occur
according to two possible pathways, considering the epithelium
structure: paracellular (or intercellular) and/or transcellular (or
intracellular), with the paracellular route being used most fre-
quently [17–19].
Structural variables and differences among the oral mucosa
regions (considering thickness, keratinization, and lipid compo-
sition) can influence drug delivery [20,21]. Differences in epithe-
lium permeability have been demonstrated, with permeability
increasing in the order: hard palate < buccal mucosa < floor of
the mouth mucosa [13,22]. As a result, topical anesthesia is less
likely to be successful in the hard palate than in any other
mucosa region [8,23].
In addition, permeation across the oral mucosa epithelium
can be affected by biological factors (age and tissue condition),
physicochemical characteristics of the drug (size, partition coef-
ficient, diffusion coefficient, and solubility), and other character-
istics such as the final dosage form and application method
(considering occlusion ability, viscosity, drug concentration, fre-
quency of application, and mucoadhesive properties) [19,20].
Due to the effectiveness of the oral mucosa barrier against
drug penetration, successful transbuccal drug delivery, including
topical anesthesia, remains a great challenge [18]. Therefore,
efforts have been focused on increasing drug penetration and
retention in order to achieve topical anesthesia success.
3. Chemical methods
Chemical methods are important tools for improving dental
topical anesthesia. Table 1 summarizes the clinical trials
conducted to evaluate topical anesthetic efficacy of LAs in
humans.
3.1. Nanostructured carriers
Previous reviews have been published concerning DDSs based
on technologies including liposomes, biopolymers, CDs, lipid
nanoparticles, hydrogels, and patches, designed to prolong the
anesthetic effect and to decrease the toxicity of LAs in infiltrative
administration in medicine and dentistry [36], and for skin
anesthesia [37]. Specific focus on DDSs for topical anesthesia
on oral mucosa was outside the scope of these revisions, so this
topic is therefore addressed in the present review.
3.1.1. Liposomes
Liposomes are lipid vesicles formed after agitation of phos-
pholipids in water. They can have one or more lipid bilayers,
where the hydrophobic lipid tails are directed toward the core
and the polar heads face the bilayer surface, in contact with
the aqueous phase. Liposomal drug delivery is a technological
platform with recognized clinical acceptance, since a variety of
drugs can be encapsulated into liposomes [38]. Because lipo-
somes are typically made from natural lipid molecules, they
are biocompatible [39], biodegradable, nontoxic [40], and
show no or very little immunogenicity [39,41]. Although lipid
bilayers present an intrinsic immune-adjuvant effect [42] that
is potentiated in modified (pegylated and cationic) liposomes
[41,43], there are no reports on adverse immune effects of
liposomes topically administered in the mouth.
The first report regarding the use of LAs encapsulated in
liposomes was in 1996. Zed and coworkers [24] demonstrated
that the topical application of a liposomal 5% tetracaine for-
mulation provided better pain relief than a 20% benzocaine gel
during infiltrative injection of 4% prilocaine in 30 volunteers.
Liposome-encapsulated ropivacaine in a Carbopol® gel for-
mulation applied to oral mucosa prior to LA injection improved
the pain relief of needle insertion in a simulated local anesthe-
sia procedure in healthy volunteers [32,35]. However, it was
Figure 2. Schematic illustration of the composition of the keratinized (a) and non-keratinized (b) oral mucosa.
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demonstrated that the same liposomal formulation or other
commercially available topical anesthetic formulations, includ-
ing EMLA, were not able to reduce the pain during LA injection
into the palatal mucosa [8].
In another study, a liposome-encapsulated 5% lidocaine
formulation presented high in vitro permeation through por-
cine palatal epithelium. The same formulation showed topical
anesthetic efficacy equivalent to that of EMLA, and both were
able to reduce pain during needle insertion and LA injection in
the palatal mucosa of healthy volunteers [10].
In addition, Paphangkorakit and coworkers [9] compared a
liposomal 2% lidocaine formulation and a commercial gel
(18% benzocaine/2% tetracaine), both used to reduce pain
during anesthetic injection in the palatal mucosa of healthy
volunteers. Despite the imprecise and unsophisticated meth-
odologies employed for liposome preparation (vibration of an
equimolar egg phosphatidylcholine:cholesterol mixture during
1 min, in an ultrasonic dental scaler) and anesthesia verifica-
tion (repeated pin-pricks using a split-mouth, unblinded
anesthesia protocol), the liposomal formulation showed better
results than the commercial formulation.
The greater permeability of the oral mucosa (up to 4000
times more permeable, compared to intact skin [13]) would
suggest that some of the liposome-encapsulated LA applied
to this mucosa could penetrate the cortical bone, resulting in
pulpal (tooth) anesthesia. This hypothesis was tested in human
volunteers, comparing liposomal benzocaine and ropivacaine
gels with commercial formulations [32,34,35]. Liposome-encap-
sulated 1% ropivacaine, 20% benzocaine, and EMLA were not
able to induce pulpal anesthesia after 2-min application in the
maxillary buccal fold [32]. Even after 30-min application in the
same oral region, liposomal 2% ropivacaine was not able to
induce pulpal anesthesia [35]. Furthermore, a liposomal 10%
benzocaine formulation induced longer soft tissue anesthesia
than a 20% benzocaine commercial gel, after a 2-min applica-
tion in the maxillary buccal fold, but neither formulation
induced pulpal anesthesia [34].
Hence, despite the conflicting results reported in the litera-
ture, in some cases, the encapsulation of LA into liposomes
increased topical anesthesia efficacy, suggesting that this may
be an important strategy that could be improved in order to
achieve pain-free dental anesthesia. If combined with other
nanotechnology tools (in a hybrid approach, see below), we
can look forward to the emergence of many more clinical
DDSs based on liposomal LAs in the near future.
3.1.2. CDs
CDs are cyclic oligosaccharides with a hydrophilic outer sur-
face and a lipophilic central cavity. Their basic constitution is
six or more α-1,4-linked D-glucopyranose units. CDs, especially
β-cyclodextrin (β-CD) and derivatives, offer advantages for
drug delivery including improved solubilization, protection
against physicochemical and enzymatic degradation, and
potential enhancement of absorption. CDs are useful for trans-
porting drugs through aqueous phases, enabling their parti-
tioning into membranes [36,44,45]. Most commercially
available LAs have a benzene ring that docks inside β-CD or
its derivatives. The association constants (Ka) resulting from
this interaction show that esters (tetracaine, benzocaine, and
proparacaine) present higher Ka values in comparison to
amides (bupivacaine, lidocaine, prilocaine, and ropivacaine),
hence exhibiting stronger interactions with CDs [46–52].
However, there are few studies reporting the use of LA-CD
complexes in oral mucosa topical formulations. Arakawa and
colleagues [53] investigated the ability of a low molecular
weight β-CD polymer (4–5 β-CD units cross-linked with epi-
chlorohydrin) for controlled release of drugs in a mucoadhe-
sive buccal film. A film containing water-soluble low molecular
weight β-CD polymers was prepared, using hydroxypropyl
cellulose (HPC) or poly(vinyl alcohol) (5% w/v) as a film base.
Lidocaine (0.5%) was complexed with this β-CD polymer and
the in vitro release of lidocaine in artificial saliva was assessed.
The results showed a 40% delay in release of lidocaine from
the mucoadhesive β-CD polymer film, compared to the con-
trol base film. This was a clear demonstration that the addition
of low molecular weight β-CD polymer to the film could
control the in vitro release of the drug [53].
In 2010, Jug and coworkers [11] prepared and characterized
binary systems for bupivacaine with β-CD or β-CD polymer
(units of β-CD cross-linked with epichlorohydrin), with the aim
of producing a new buccal mucoadhesive formulation to deli-
ver bupivacaine through oral mucosa. Solid-state analysis
revealed more intense interactions of bupivacaine with the
β-CD polymer than with the native β-CD. In vitro dissolution
studies using artificial saliva in Franz diffusion cells demon-
strated that it was possible to change the dissolution charac-
teristics of bupivacaine by complexation with CDs. The drug
dissolution rate was reduced for bupivacaine complexed with
native β-CD, and increased with the β-CD polymer. Therefore,
the authors suggested that the bupivacaine release rate could
be modulated according to the desired effect, with rapid onset
of anesthesia for simple dental procedures, or prolonged
effects in postsurgical procedures.
Animal studies of the toxicity of β-cyclodextrin have indi-
cated that nephrotoxicity may occur following infiltrative
administration [54]. However, β-CD derivatives such as hydro-
xypropyl-β-CD and sulfobutyl-β-CD are less toxic and have
been approved by the FDA for injection [36].
The use of CD formulations directly on mucosa is consid-
ered safe for both natural CDs and their hydrophilic deriva-
tives in a broad range of concentrations, while in the case of
methylated CD derivatives, the concentration and duration of
application should be monitored [55]. Boulmedarat and cow-
orkers [44] evaluated the toxicity of randomly methylated β-
CD in a buccal mucosa model (reconstituted human oral
epithelium). Measurements were made of cell viability (MTT
assay), membrane damage (lactate dehydrogenase release),
and inflammatory effects (expression of interleukin-1α). The
results indicated cytotoxic and inflammatory effects of 10%
methylated β-CD, depending on the time of exposure. Lower
concentrations (2% or 5%) did not induce any damage in the
buccal tissue.
3.1.3. Lipid nanoparticles
The first and second generations of lipid nanoparticles, namely
SLNs and NLCs, respectively, were developed as alternatives to
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the existing nanosystems in an attempt to overcome limita-
tions of liposomes such as poor physicochemical stability and
low encapsulation efficiency for hydrophobic drugs. SLNs and
NLCs are very similar nanocarriers, differing in their internal
matrices. The SLN matrix consists of solid lipids, while NLCs are
composed of a blend of solid and liquid lipids, with the
resulting internal disorganization leading to better entrap-
ment of a drug and prevention of its expulsion over time.
However, the ability of these lipid nanosystems to encapsulate
hydrophilic molecules is lower, compared to liposomes. They
have been studied since the 1990s and are excellent options
for use in DDSs for topical application, due to their nanometric
size, large contact surface area, biocompatibility, biodegrad-
ability, and occlusive effect, which improves the permeation of
active molecules [56]. SLNs and NLCs have been successfully
used for targeting drugs such as cyclosporine A, curcumin,
clotrimazol, and miconazole to the oral mucosa, proving
their potential as excellent carriers for use in transbuccal
administration [57–60].
Only a few studies have been published concerning the
encapsulation of LA by SLNs and NLCs for topical applica-
tions, most of them involving transdermal delivery. NLCs
loaded with lidocaine and benzocaine have exhibited desir-
able physicochemical properties, excellent in vitro permea-
tion, sustained release profiles, and absence of cytotoxic
effects [61–63].
In the case of the transbuccal route, no studies have yet
been published concerning lipid nanoparticle systems for
topical anesthesia. However, it is worth mentioning a study
[64] in which optimized NLC systems for lidocaine–prilocaine
presented physicochemical stability during up to 14 months
of storage at 25°C, in terms of size, polydispersity index, and
zeta potential. The release of the anesthetics was sustained
for up to 20 h and the system protected both LAs against
degradation. Rapid onset and long duration of anesthesia
indicated the potential of the system for transbuccal topical
anesthesia.
Nevertheless, the low viscosity of the colloidal systems men-
tioned above is not desirable for topical anesthesia of oralmucosa,
because an efficient adhesion is required [65]. Recent advances in
pharmaceutical nanotechnology include the exploration of hybrid
approaches such as combinations of lipid and PN systems, nano-
particles and polymer-based topical pharmaceutical forms, nano-
particles and physical methods, and polymer-based topical
pharmaceutical forms and physical methods (Figure 3). These
multiple associations combine the best properties of each excipi-
ent in the final formulation [66] and they can provide versatile
strategies for the development of new and improved mucoadhe-
sive formulations that are engineered to present sustained release
profiles (smart DDSs). Wang et al. [67] compared the performance
of liposomes and lipid–polymer hybrid nanoparticles with encap-
sulated lidocaine for topical application. The lipid–polymer hybrid
nanoparticles showed smaller particle size (<100 nm) and higher
encapsulation efficiency (>85%) than liposomes, as well as the
best in vitro sustained release and permeation profile of lidocaine.
Studies have also described the incorporation of SLN dispersions
into biopolymeric matrices to produce different mucoadhesive
formulations, such as lipid–polymer gels and sponges, for the
transbuccal release of curcumin [68,69].
3.1.4. PN systems
PNs are able to permeate the oral mucosa [70]. They can typically
be prepared as polymeric micelles, nanospheres, and nanocap-
sules [71]. These nanosystems have been successfully used for
transbuccal applications, due to their nanometric sizes, sustained
release profiles, and good adhesion. Applications include cancer
and periodontic treatments, as well as reduction of tooth hyper-
sensitivity [72]. Despite their useful properties, to date, there are
no reports regarding the use of these nanocarriers in topical
transbuccal anesthesia.
However, LAs encapsulated in different PNs have been widely
reported for a variety of applications. Optimized formulations of
benzocaine loaded in poly-(D,L-lactide-co-glycolide) nanocapsules
have been described, with desirable structure-dependent proper-
ties and sustained release profiles [73]. Nanocapsules based on
poly(L-lactide) showed longer anesthetic action after sensory scia-
tic nerve blockade in mice, compared to other benzocaine-loaded
PNs [74]. Alginate nanoparticles encapsulating bupivacaine were
able to reduce the toxicity of the LA and prolong the anesthetic
effect in mice [75]. The delivery of lidocaine using nanospheres
based on poly(ε-caprolactone) resulted in increased intensity and
duration of in vivo anesthesia in sciatic nerve blockade inmice [76].
Figure 3. Schematic representation of drug delivery systems and physical methods used to increase topical anesthetic efficacy, as well as their possible
combinations to achieve a better anesthetic effect and their possible clinical applications.
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De Melo et al. [77] evaluated different polymeric nanocarriers for
articaine delivery. The best nanocapsule system was composed of
poly(ethylene glycol)-poly(ε-caprolactone). This systemminimized
the toxicity of the drug and exhibited sustained in vitro release,
probably due to strong interaction between articaine and the
aqueous nucleus of the nanocapsule. These achievements support
the potential use of PNs for topical anesthesia of oral mucosa.
3.2. Polymer-based topical pharmaceutical forms: bio-
and mucoadhesive films, patches, and hydrogels
The main drawbacks of topical administration of drugs to the
oral mucosa using traditional semisolid formulations is the
short time of contact with the tissue, resulting in a low efficacy
of the treatment, as well as the lack of unidirectional drug
release, which can lead to systemic absorption.
The use of biopolymers as matrices for the incorporation of
therapeutic agents is a versatile strategy that confers important
properties on the systems, such as protection from photoche-
mical degradation, a sustained release profile, and adequate
swelling, permeation, and mucoadhesion, besides the possibi-
lity of unidirectional drug release. The resultant materials are
extensively used as DDSs [78] and can be prepared as hydro-
gels, films, and patches, circumventing the limitations of the
oral mucosa route. Lidocaine, the gold-standard LA in dentistry,
has been extensively studied for sustained delivery systems
targeting the oral mucosa [79–81]. However, reports about
systems incorporating other LAs still remain scarce.
In 1996, the FDA approved DentiPatch™ (Noven Pharmace-
uticals, Inc.), the first ‘lidocaine transoral delivery system intended
to provide topical anesthesia for the prevention of pain from
injection and soft tissue dental procedure’ [82]. DentiPatch con-
tains 41.6 mg of lidocaine in 2 cm2 of a karaya gum adhesive
matrix, covered by a polyester film, and according to the manu-
facturer is able to induce anesthesia in 2.5 min. Its safety and
efficacy have been proved in both adults [28,29,31,83,84] and
children [30,33,85–87], although poor adhesion to oral mucosa
has been reported [30].
Almost all films and patches can generally be prepared by
the casting/solvent evaporation technique, but other methods
have also been described, such as the lamination technique
and hot-melt extrusion. The most widely studied cellulose
derivative for the formulation of buccal films containing LA is
HPC [26,27,81,88–90]. Films of HPC have been successfully
used in vivo for relief of the pain of oral diseases. Yamamura
et al. [27] used a three-layer HPC mucosa-adhesive film con-
taining dibucaine for the treatment of oral ulcer. Oguchi et al.
[26] employed a film of HPC containing tetracaine, in associa-
tion with other drugs, for treating acute radiation-induced oral
mucositis. The association of HPC with hydroxypropyl methyl
cellulose (HPMC) or ethyl cellulose (EC) has proven to be
useful in modulating drug release and for film mucoadhesion
in vitro. In particular, the use of HPMC in combination with
HPC for the preparation of hot-melt extruded films containing
lidocaine promoted increased adhesion to intestinal rabbit
mucosa (used as a biological substrate model) and a decrease
of the lidocaine release rate, indicative of a prolonged analge-
sic effect [90]. The addition of EC to HPC solid dispersion films
enabled modulation of lidocaine release, with an optimum
obtained when the polymers were used in a 1:1 ratio. The
optimized film showed significant mucoadhesion to the buc-
cal mucosa in vivo in men [88].
An alternative to cellulose derivatives is provided by
Carbopol, a water-insoluble acrylic polymer that shows good
bioadhesion. Abu-Huwaij et al. [91,92] proposed mucoadhe-
sive Carbopol films for the delivery of lidocaine hydrochloride.
The mucoadhesive properties were influenced by the type
and concentration of the plasticizer used, as well as by the
concentration of lidocaine, which interacted with the polymer
and reduced its bioadhesion [91]. The coupling of this film
with an ethyl vinyl acetate backing, in order to ensure unidir-
ectional drug release, together with the introduction of per-
meation enhancers such as oleic acid and Tween, amongst
others, significantly prolonged the permeation of lidocaine
across pig buccal mucosa, compared to a control solution.
The system also showed good in vivomucoadhesion in rabbits
[92]. A Carbopol film containing HPMC was developed by
Cavallari [79] for the buccal delivery of lidocaine. A hybrid
approach, using the addition of Compritol microspheres con-
taining lidocaine, resulted in a bimodal controlled release of
the drug, with 40% release in 30 min and 100% release in 3 h.
Finally, poly(vinyl alcohol) was used in the development of
a film for the buccal delivery of lidocaine, produced by the
lamination technique [93]. The association with an acrylic
polymer improved the transport of lidocaine across pig eso-
phageal epithelium (used as a buccal mucosa model), possibly
due to greater mucoadhesion of the film.
Hydrogels are tridimensional semisolid substances com-
posed of networks of natural or synthetic polymers, with
functional groups that interact synergistically with mucosal
tissue. Their advantages as bases for topical anesthetic formu-
lations include biodegradability, easy handling, patient com-
pliance, softness, mucoadhesion, and rapid onset of
anesthesia [94].
Abdel-Hamid et al. [95] proposed the application of mebever-
ine (an antispasmodic agent) as a LA contained in Poloxamer-407
hydrogels for the treatment of painful oral conditions such as
lichen planus, recurrent aphthae, erythema multiforme, and
Behçet’s syndrome. Clinical evaluation of pain reduction efficiency
showed a greater anesthetic effect of the proposed hydrogel,
compared to a commercially available formulation, together with
improved wound healing of the buccal mucosa.
Xu et al. [96] developed hydrogels based on genipin-cross-
linked catechol–chitosan for the buccal mucosa delivery of lido-
caine as a model drug. A hydrogel was obtained that showed
good in vitro mucoadhesion to porcine buccal mucosa tissue,
together with good mechanical and rheological properties.
Evaluation of the in vivo drug release in rabbits confirmed the
sustained release profile. Similarly, Pignatello et al. [97] suggested
a mucoadhesive lidocaine-loaded hydrogel for buccal applica-
tions, based on chitosan glutamate, with clinical evaluation con-
firming the potential of the formulation to minimize pain
associated with oral mucosa disorders.
Hirsh et al. [98] patented a gelled anesthetic preparation for
oral and buccal mucosa application, which was especially
indicated for the treatment of periodontal pockets. The for-
mulation showed adequate viscosity and adhesion and pro-
vided long-term gingival anesthesia. The LAs that were most
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compatible with the excipients of this patented formulation
included benzocaine, tetracaine, and butamben, as well as
blends of these drugs.
These interesting studies suggest the ability of biopolymers
to act as excellent matrices for the incorporation of other LAs
in the preparation of mucoadhesive transbuccal formulations.
4. Physical methods
Several physical methods are able to reduce pain during
needle insertion and LA injection. They are also used to
improve the efficacy of topical anesthetic agents applied to
the oral mucosa. One of the most widely reported methods is
the precooling technique.
Cryoanesthesia is based on the application of ice or cold to a
surface area of the body, causing reduction of action potentials
and resulting in sensorial nerve conduction blockade [99]. In
dentistry, application of precooling to oral mucosa prior to LA
infiltration can alter the perception of pain. Harbert et al. [100]
observed reduced pain perception during LA infiltration when
ice was applied topically on the palatal mucosa before and
during the infiltration. Duncan et al. [101] reported relief of
the discomfort caused by needle insertion after applying a
cotton pellet saturated with dichlorodifluoromethane spray for
5 s on a small portion of palatal tissue.
Kosaraju and Vandewalle [102] used a split-mouth design in
16 volunteers to compare the topical anesthesia effectiveness
of a refrigerant spray (1,1,1,3,3-pentafluoropropane/1,1,1,2-tet-
rafluoroethane) applied during 5 s and a 20% benzocaine gel
applied during 2 min, both used prior to a palatal anesthetic
injection. The volunteers rated their experience using a visual
analog scale (VAS). The refrigerant spray was more effective
than the benzocaine gel in reducing the pain during injection.
Lathwal et al. [99] compared the effects of the same refriger-
ant spray (5 s), benzocaine (1 min), and ice (1 min) on pain
perception during bilateral local anesthesia nerve block in 160
patients aged between 5 and 8 years. Significantly higher
anesthesia efficacy was observed for ice, compared to benzo-
caine or the refrigerant spray.
In other work, 160 patients aged between 5 and 6 years
were randomly allocated to receive pretreatment with topical
anesthesia, alone or with ice cooling, before administration
of inferior alveolar nerve blockage. A significant reduction of
pain perceived during injection of the LA was observed when
ice was used [103]. Ghaderi et al. [104] used a cross-over
design in 50 healthy pediatric patients, evaluating pain per-
ception during LA buccal infiltration after using topical
anesthesia (20% benzocaine, 1 min) with or without applica-
tion of an ice pack (1 min). It was observed that cooling the
injection site before infiltration of the LA reduced the per-
ceived pain.
Overall, the use of precooling with a 5-s application of a
refrigerant spray or a 1-min application of ice seems to
improve (or to itself promote) superficial anesthesia, leading
to reduced pain perception during LA administration.
The mechanical stimulus (pressure or vibration) technique
has been used to minimize the pain experienced during admin-
istration of LA agents. The stimulation of mechanical receptors
by vibration or pressure excites inhibitory interneurons in the
spinal cord, resulting in the elimination of transfer of nocicep-
tive information by Aδ and C fibers to the second order neurons
of the spinal cord [105]. Some devices are able to cause vibra-
tion while others simultaneously produce both vibration and
pressure during injection of the anesthetic. The data published
concerning these devices remains conflicting, with some stu-
dies showing that use of the devices leads to painless injection,
while others have found no significant decrease in the percep-
tion of pain in the oral mucosa [106,107].
In contrast to these positive results obtained with the
different techniques, in terms of reduced discomfort of
anesthetic injection, Wiswall et al. [108] demonstrated that
the application of topical anesthetics, precooling, and pres-
sure did not reduce pain perception during anesthetic injec-
tion and deposition in bilateral greater palatine nerve
blockage. A cross-over study was employed, with 42 volun-
teers who received the following pretreatments: (1) no sti-
mulation; (2) pressure alone; (3) pressure + topical
anesthetic (20% benzocaine); and (4) pressure + cold
(1,1,1,2-tetrafluoroethane). The pain perception was rated
using the Heft-Parker VAS, and no significant differences
were found among the pretreatments. In addition, 1,1,1,2-
tetrafluoroethane caused injuries in the oral mucosa when
used together with pressure for 10 s [108].
Other different approaches, such as iontophoresis and micro-
needle arrays, have been studied in the last decade in order to
achieve deeper and more effective topical anesthesia in the oral
mucosa. Iontophoresis is a technique based on the application of
a low-density electric current to facilitate the transfer of drugs
through biological membranes. Iontophoresis is used in medi-
cine for transdermal drug delivery but has been little explored in
transbuccal delivery.
Hu et al. [109] studied the use of iontophoresis to enhance
transdermal and transmucosal delivery of lidocaine and other
drugs. The authors performed in vitro transdermal and trans-
buccal permeation experiments in Franz diffusion cells, using
porcine skin and buccal tissues. The application of iontophor-
esis enhanced drug delivery, with a greater effect on transder-
mal than on transbuccal permeation.
Cubayachi et al. [110] recently evaluated the use of ionto-
phoresis to enhance the permeation of prilocaine and lidocaine
salts, combined in a mucoadhesive semi-solid formulation. In
vitro studies were performed using pig esophageal mucosa as a
barrier to simulate buccal mucosa. Iontophoresis resulted in
increased retention of the LAs in the mucosal epithelium.
Although only in vitro data were available, the authors hypothe-
sized that this strategy might be used in needle-free applica-
tions in buccal anesthesia.
Microneedles have been extensively studied as a mechanical
technology for transdermal delivery [111]. They are sufficiently
long to cross the epithelium barrier and deliver the drug, but
short enough to avoid the free nerve endings located in the
dermal and lamina propria layers [112]. Kochhar et al. [113]
observed high transdermal delivery and a faster onset of anesthe-
sia for lidocaine inmicroneedles in a transdermal patch, compared
to a traditional patch. In other work, porcine skin pretreated with
microneedles showed enhanced permeation of a formulation
of lidocaine in a sodium carboxymethyl cellulose/gelatin
hydrogel [114].
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Other studies have also investigated microneedle-based
drug delivery for transdermal applications [115], and the use
of coated microneedles has been reported to be a successful
method for the delivery of lidocaine across pig skin [116]. The
combination (in a hybrid approach) of drug encapsulation in
nanoparticles and the use of coated microneedles has also
been described for buccal topical use. Microneedles coated
with doxorubicin encapsulated in PNs (poly(lactic-co-glycolic)
acid) were found to effectively promote uniform distribution
of the drug in a porcine cadaver buccal tissue [117].
Despite the lack of studies to demonstrate that the use of
microneedles significantly increases the effectiveness of topi-
cal anesthetic in oral mucosa, this physical method (as well as
its combination with other DDSs) seems to be a promising
tool for use in future clinical studies.
5. Conclusions
Different DDSs and pharmaceutical dosage forms have been suc-
cessfully developed with the aim of increasing the effectiveness of
topical anesthesia in oral mucosa. Most of these promising for-
mulations have shown interesting properties in vitro. Although
there have been only a few in vivo clinical trials, these studies have
confirmed the pharmacological improvements, especially in the
case of liposomal formulations. In addition, the precooling of oral
mucosa has been shown to be a valid tool for promoting pain-free
local anesthesia. The continuing development of new systems and
formulations for clinical use in the oral cavity will help to achieve
significant improvements in topical oral anesthesia.
6. Expert opinion
Even today, it is utopic to conceive of a single nanosystem
that might solve all the requirements for drug delivery in the
oral mucosa, as reflected in the disappointing results for some
of the clinical trials listed in Table 1. Despite substantial
advances in pharmaceutical nanotechnology, including in
dentistry, all the current systems have limitations in applica-
tions involving the oral mucosa. In order to select the most
appropriate topical nanosystem, it is crucial to consider the
physicochemical properties of the anesthetic agent and the
specific characteristics of the site of administration (such as
the gingival or palate mucosa). The use of a suitable excipient
to maintain the drug at the site of application increases the
potential success of the formulation, as shown for cyclodex-
trin, lipid-based, and polymeric nanosystems.
The association of two or more DDSs, in nanohybrid
approaches (Figure 3), seems to be the most promising strategy
to achieve successful topical anesthesia in the oral mucosa, com-
bining the desirable properties of each material in the pharma-
ceutical formulation. The systems can be tailored to behave
according to specific features of the oral cavity, such as tempera-
ture, humidity, salivary flow, free ions available in saliva, and the
anionic mucosal surface. This can result in synergism between the
formulation components and the biological interface, creating
smart DDSs. The main objective, which remains a challenge, is
the creation of a versatile material able to remain functional
despite the large number of physiological variables that can hin-
der the success of formulations. Further development of
nanohybrid approaches associated with physical methods seems
to be the best way forward in terms of improved superficial
anesthesia.
The use of biopolymers also deserves more attention, since
these are derived from inexpensive, biocompatible, abundant,
and multifunctional raw materials. In addition, multidisciplin-
ary tools can be used to help in elucidating the performance
of each component, as well as the interactions among them in
the final formulation. This can minimize the likelihood of fail-
ure of the formulation and enable extrapolation to the deliv-
ery of other drugs by the transbuccal route.
An effective anesthetic formulation intended for topical oral
applications should have additional clinical benefits besides the
prevention of pain during dental anesthesia. An effective formu-
lation could also provide postoperative pain control, treatment
and/or analgesia of painful mucosal conditions such as oral ulcers
and mucositis, gingival anesthesia prior to rubber dam clamp
placement, scaling, and root planing, and anesthesia in soft tissue
biopsy. These aspects have been considered in several of the
clinical trials mentioned in Table 1 (as proposed in Figure 3).
Among all the possible advantages, one should be highlighted,
namely topical anesthesia to replace traditional dental anesthesia,
hence enabling needle-free dental treatment. In terms of this
goal, conflicting results have been reported. Although some
studies have reported positive results [25,118–120], others have
failed to reach such conclusions [32,34,35,121,122]. Nonetheless,
this remains the greatest aspiration among both patients and
clinicians in dentistry.
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